Read our latest publications
Measuring up 2018 is a five-year bibliometric analysis of the scientific publication output of Australian health and medical research, focusing on research funded by the National Health and Medical Research Council (NHMRC).
This Report from NHMRC’s Research Quality Workshop on 30 July 2019 outlines key messages, activities and initiatives within the research sector, and potential opportunities for collaboration to ensure the conduct of high quality research. Outcomes from the workshop will inform NHMRC’s ongoing activities to ensure the highest quality in NHMRC-funded research.
NHMRC’s Policy on Recognition acknowledges the role of Partners who support NHMRC in health and medical research. It sets out a strategy to recognise current and potential NHMRC Partners and how Partners recognise NHMRC.
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2018 - 2019.
Reference number: NH181
ISSN Print: 2209-7090
ISSN Online: 2209-7104
Payment of participants in research: information for researchers, HRECs and other ethics review bodies
NHMRC has developed advice that is designed to provide information for researchers and reviewers of research to assist in decision-making about when payment of participants in research is ethically acceptable.
The fundamental framework for the ethical, humane and responsible care and use of animals for scientific purposes in Australia includes the application of the 3Rs – Replacement, Reduction and Refinement of animal use. This Information Paper provides information about the implementation of the 3Rs in Australia. For further information, please refer to the webpage about the 3Rs.
The NHMRC Corporate Plan 2019-20 covers the period 2019-20 to 2022-23. It identifies the major health issues for this period, how we will deal with these issues and a strategy for medical research and public health research, in line with the requirements of the NHMRC Act. It also describes NHMRC’s purposes, planned activities and performance measures for the period and addresses our capability, environment and risk oversight and management.
The 34th biannual report
This report advises the NHMRC Chief Executive Officer on the current needs for research and clinical guidance for ME/CFS in Australia.
The guidelines are produced by the National Health and Medical Research Council in collaboration with the Australian Commission on Safety and Quality in Healthcare, and are accessible in two formats: a new IT platform (MAGICapp), or via a pdf (see 'Download' section below)
Ensuring the highest quality and value of NHMRC-funded research is a priority for NHMRC. NHMRC’s Research Quality Strategy outlines the key areas NHMRC will focus on to provide guidance and support for good research practices throughout the research cycle.
Linked to Road Map 3: A Strategic Framework for Improving Aboriginal and Torres Strait Islander Health through Research (Road Map 3)
The 32nd biannual report.
The aim of NHMRC's Gender Equality Strategy is to achieve a gender-equal health and medical research workforce by supporting an increase in the retention and progression of women.
In conjunction with the Australian Clinical Trials Alliance, we developed the clinical trials competencies to be used in the development of detailed curricula and training courses by universities, Colleges and other registered training organisations.
To improve clinical trial start-up times, we developed the Good Practice Process for Site Assessment and Authorisation Phases of Clinical Trial Research Governance (the Good Practice Process).
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2017–18.
Ten of the Best NHMRC Research Projects 2016 describes ten Australian health and medical research projects chosen from among the thousands of NHMRC funded medical research projects underway in Australia today.
The NHMRC Corporate Plan 2018–2019 covers the period 2018–19 to 2021–22. It identifies the major health issues for this period, how we will deal with these issues and a strategy for medical research and public health research, in line with the requirements of the NHMRC Act. It also describes NHMRC’s purposes, planned activities and performance measures for the period and addresses our capability, environment and risk oversight and management.
The National Statement on Ethical Conduct in Human Research (2007) (National Statement (2007) consists of a series of guidelines made in accordance with the National Health and Medical Research Council Act 1992.
The 31st biannual report.
The Australian Code for the Responsible Conduct of Research, 2018 (the 2018 Code) establishes a framework for responsible research conduct that provides a foundation for high-quality research, credibility and community trust in the research endeavour.
Road Map 3: A strategic framework for improving Aboriginal and Torres Strait Islander health through research. Report of Community Consultation.
A useful guide explaining key terms used in embryo research. Provides definitions of the main terms used, including biological definitions and therapy explanations.
This report contains information on our organisation, administration and performance for the reporting period 2016–17. It is a record of our activities during 2016–17 and the performance and financial information presented in the 2016–17 Portfolio (Agency) Budget Statement, 2016–17 Portfolio Additional Estimates Statement and the Corporate Plan 2016–2017.
This Kit is divided into five chapters, covering different aspects of the NHMRC Embryo Research Licensing Committee’s activities:
Managing individual exposure to lead in Australia – A guide for health practitioners (The Guide) provides health practitioners with general information to assist in the management of individuals with elevated blood lead levels.
This document provides advice on the conduct of animal-based studies to ensure that the studies are rigorous, transparent and reproducible and lead to useful outcomes. It is in line with the Australian Code for the care and use of animals for scientific purposes, 8th edition (2013), which is adopted into legislation across Australia.
This strategic plan outlines the major objectives of the NHMRC over the next three years, the major health issues that may emerge in the coming years and the steps needed to address them.
Based on a comprehensive review of the evidence and the translation of this evidence into the Information Paper Water fluoridation: dental and other human health outcomes, this also takes into consideration what the situation is here in Australia compared to elsewhere.
The 30th biannual report.
The NHMRC Corporate Plan 2017–2018 covers the period 2017–18 to 2020–21. It includes NHMRC’s strategic directions, which prior to 2015–16 were set out in the strategic plan.
This Information Paper explores the potential link between water fluoridation and human health based. The 2016 NHMRC Evidence Evaluation shows that water fluoridation helps to reduce tooth decay in children and adults. There is no reliable evidence that water fluoridation at current Australian levels causes health problems.
The Ethical guidelines on the use of assisted reproductive technology in clinical practice and research (ART guidelines) are used by professional organisations to set standards for the practice of ART.
The 29th biannual report.
This document clarifies the responsibilities of those involved in clinical trials to monitor and report adverse events and other safety issues. Supplementary guidance on other clinical trial safety monitoring and reporting issues is also available.
This report was prepared in accordance with Public Governance, Performance and Accountability (non-corporate Commonwealth Entity) Annual Reporting Rule 2016. It contains information on NHMRC’s organisation, administration and performance for the reporting period 2015–16.
This document provides principles and best practice guidance for the care and use of non-human primates for scientific purposes. The document is intended for use by those involved in the care and use of non-human primates for scientific purposes, including institutional animal ethics committees, investigators and animal carers.
The Statement on consumer and community involvement in health and medical research (The Statement), co-authored by the National Health and Medical Research Council (NHMRC) and the Consumers Health Forum of Australia (CHF), aims to guide research institutions, researchers, consumers and community members in the active involvement of consumers and community members in all aspects of health and medical research.
The NHMRC Corporate Plan 2016–2017 covers the period 2016–17 to 2019–20. It includes NHMRC’s strategic directions, which prior to 2015–16 were set out in the strategic plan.
The 28th biannual report.
The International Engagement Strategy outlines our approach to prioritising new and existing activities with our international partners over the next three years.
The NHMRC Complaints Policy sets out NHMRC’s formal procedures for responding to complaints about its activities, policies or decision-making.
Ten of the Best NHMRC Research Projects 2015 describes ten Australian health and medical research projects chosen from among the thousands of NHMRC funded medical research projects underway in Australia today.
The Ethical guidelines for organ transplantation from deceased donors were developed by NHMRC following a joint request from the Organ and Tissue Authority and the Transplantation Society of Australia and New Zealand.
This book contains key statistics on the outcomes of the 2014 application rounds for NHMRC’s research funding, as well as historical information relating to research funding and activity over the last ten years.
The 27th biannual report.
A guide to the legislative and governance structure to refer to when accessing datasets from publicly funded research. This page also contains a single page summary to the guide and a consumer guide.
The 26th biannual report.
This Corporate Plan sets out NHMRC’s purposes, planned activities and performance for the period 2015–16 to 2018–19, and addresses capability, environment and risk oversight and management in line with PGPA Act requirements.